Delving into the Latest Updates on Jiangsu Xiansheng Biopharmaceutical Co. Ltd. with Synapse

Overview

Tags

Neoplasms

Digestive System Disorders

Urogenital Diseases

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Hemic and Lymphatic Diseases	1
Immune System Diseases	1
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Monoclonal antibody	2

Top 5 Target	Count

VEGF-A(Vascular endothelial growth factor A)	1
TNFR2(Tumor necrosis factor receptor superfamily member 1B)	1

Ib期主要目的：评价苏维西塔单抗联合曲氟尿苷替匹嘧啶片的安全性和耐受性。 Ib期次要目的：1. 评价苏维西塔单抗的药代动力学（PK）和免疫原性；2. 评价苏维西塔单抗联合曲氟尿苷替匹嘧啶片在难治性转移性结直肠癌受试者中的初步抗肿瘤活性。 III期主要目的：评价苏维西塔单抗联合曲氟尿苷替匹嘧啶片在难治性转移性结直肠癌受试者中的有效性。 III期次要目的：1. 进一步评价苏维西塔单抗联合曲氟尿苷替匹嘧啶片在难治性转移性结直肠癌受试者中的有效性；2. 评价苏维西塔单抗联合曲氟尿苷替匹嘧啶片在难治性转移性结直肠癌受试者中的安全性特征 3. 评价苏维西塔单抗联合曲氟尿苷替匹嘧啶片对难治性转移性结直肠癌受试者生活质量的影响；4. 评价苏维西塔单抗联合曲氟尿苷替匹嘧啶片的PK和免疫原性。 III期探索性目的：探索PK、药效学、安全性和临床有效性之间的关系。

[Translation]

Phase Ib primary objective: To evaluate the safety and tolerability of suvicidumab in combination with trifluuridine ticipiramycin tablets. Phase Ib secondary objectives: 1. To evaluate the pharmacokinetics (PK) and immunogenicity of suvicidumab; 2. To evaluate the preliminary antitumor activity of suvicidumab in combination with trifluuridine ticipiramycin tablets in patients with refractory metastatic colorectal cancer. Phase III primary objective: To evaluate the efficacy of suvicidumab in combination with trifluuridine ticipiramycin tablets in patients with refractory metastatic colorectal cancer. Phase III Secondary Objectives: 1. To further evaluate the efficacy of suvicetumab in combination with trifluuridine tepiraprazine in patients with refractory metastatic colorectal cancer; 2. To evaluate the safety profile of suvicetumab in combination with trifluuridine tepiraprazine in patients with refractory metastatic colorectal cancer; 3. To evaluate the impact of suvicetumab in combination with trifluuridine tepiraprazine on the quality of life of patients with refractory metastatic colorectal cancer; 4. To evaluate the pharmacokinetics (PK) and immunogenicity of suvicetumab in combination with trifluuridine tepiraprazine. Phase III Exploratory Objectives: To explore the relationship between PK, pharmacodynamics, safety, and clinical efficacy.

Start Date-

Sponsor / Collaborator

Jiangsu Xiansheng Biopharmaceutical Co. Ltd.

100 Clinical Results associated with Jiangsu Xiansheng Biopharmaceutical Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Jiangsu Xiansheng Biopharmaceutical Co. Ltd.

Login to view more data

100 Deals associated with Jiangsu Xiansheng Biopharmaceutical Co. Ltd.

Login to view more data

100 Translational Medicine associated with Jiangsu Xiansheng Biopharmaceutical Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 19 Feb 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1

1

Approved

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Sevacizumab ( VEGF-A )	Recurrent Platinum-Resistant Fallopian Tube Carcinoma More	Approved
SIM1811-03 ( TNFR2 )	Advanced Malignant Solid Neoplasm More	Phase 1